{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:06:40Z","timestamp":1789387600407,"version":"build-2803163510"},"reference-count":402,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Esophageal carcinoma (EC) remains one of the most lethal malignancies, with a five-year survival rate of only 15-25% in advanced stages. Although immunotherapy including immune checkpoint inhibitors (ICIs) and antibody-based therapies have improved clinical outcomes, durable responses are confined to a minority of patients because primary and acquired resistance affect the majority. The tumor microenvironment (TME)\u2014composed of immune cells, stromal cells, and the extracellular matrix\u2014has emerged as a central driver of the immune resistance, wherein infiltrating immune cells and stromal cells form suppressive networks that impair cytotoxic immunity and foster tumor progression. However, a coherent framework linking clinical practice, TME-mediated resistance mechanisms, and therapeutic strategies remains lacking. In this review, we dissect the cellular and molecular basis of TME-driven immune resistance in EC, summarize established and emerging immunotherapies, and evaluate strategies to overcome treatment failure, including TME-targeted therapy, metabolic modulation, photodynamic therapy, and mechanism-guided combination approaches. These insights reframe immunotherapy resistance as a TME-driven process rather than a purely tumor-intrinsic defect, underscoring the need to concurrently target malignant cells and their surrounding immunosuppressive niche. Ultimately, elucidating TME heterogeneity and its dynamic evolution is essential to convert resistant EC into an immunotherapy-responsive disease and to guide precision combination strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1926551","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:38:01Z","timestamp":1789385881000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunosuppressive tumor microenvironment and immunotherapy resistance of esophageal carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhenglin","family":"He","sequence":"first","affiliation":[{"name":"Department of Biobank, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanming","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, College of Basic Medical Sciences, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Biobank, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Ren","sequence":"additional","affiliation":[{"name":"School and Hospital of Stomatology, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishuo","family":"Ji","sequence":"additional","affiliation":[{"name":"The First Hospital of Jilin University, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine","place":["New Haven, CT, United States"]},{"name":"Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale University","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biobank, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]},{"name":"Department of Endoscopy Center, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pathology, China-Japan Union Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Biobank, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70090","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-026-02614-7","article-title":"Esophageal cancer: from pathogenesis to precision therapies","volume":"11","author":"Zhang","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.athoracsur.2024.04.034","article-title":"Multimodal treatment of resectable esophageal cancer","volume":"119","author":"Waters","year":"2025","journal-title":"Ann Thorac Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1566939","article-title":"The efficacy and safety of PD-1\/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials","volume":"16","author":"Pu","year":"2025","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10388-022-00970-1","article-title":"First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648\/ONO-4538-50)","volume":"20","author":"Kato","year":"2023","journal-title":"Esophagus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"Jama"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i8.109489","article-title":"Unmasking immune checkpoint resistance in esophageal squamous cell carcinoma: Insights into the tumor microenvironment and biomarker landscape","volume":"17","author":"Wang","year":"2025","journal-title":"World J Gastrointest Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01425-7","article-title":"Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers","volume":"125","author":"Baxter","year":"2021","journal-title":"Br J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2026.2635243","article-title":"Mapping research trends in esophageal cancer immunotherapy: A decade of thematic evolution and emerging priorities","volume":"22","author":"Jia","year":"2026","journal-title":"Hum Vaccin Immunother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i16.2195","article-title":"Mechanisms of tumor immunosuppressive microenvironment formation in esophageal cancer","volume":"30","author":"Zhang","year":"2024","journal-title":"World J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654731","article-title":"Innate immune cells in the esophageal tumor microenvironment","volume":"12","author":"Cui","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189264","article-title":"Unraveling the tumor microenvironment of esophageal squamous cell carcinoma through single-cell sequencing: A comprehensive review","volume":"1880","author":"Qi","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1524801","article-title":"Metabolic reprogramming and immunological changes in the microenvironment of esophageal cancer: future directions and prospects","volume":"16","author":"Guo","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ccell.2023.03.001","article-title":"Epithelial cells activate fibroblasts to promote esophageal cancer development","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s10238-025-01944-0","article-title":"Tumor microenvironment-mediated immune evasion and resistance in prostate cancer: mechanisms, cross-talk, and therapeutic opportunities","volume":"26","author":"Li","year":"2025","journal-title":"Clin Exp Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cells14231895","article-title":"The interplay between esophageal adenocarcinoma and its tumor microenvironment: toward innovative therapies","volume":"14","author":"Fioretzaki","year":"2025","journal-title":"Cells"},{"key":"B20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Mol Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1532558","article-title":"Uncovering the role of microRNAs in esophageal cancer: from pathogenesis to clinical applications","volume":"16","author":"He","year":"2025","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2026.2641263","article-title":"Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma","volume":"27","author":"Wang","year":"2026","journal-title":"Cancer Biol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.05.010","article-title":"Integrative approaches to cancer immunotherapy","volume":"5","author":"Szeto","year":"2019","journal-title":"Trends Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","article-title":"Exploiting innate immunity for cancer immunotherapy","volume":"22","author":"Yi","year":"2023","journal-title":"Mol Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1369848","article-title":"Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03566-5","article-title":"Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03792-7","article-title":"A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.782","article-title":"Targeting esophageal carcinoma: molecular mechanisms and clinical studies","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm (2020)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14541","article-title":"Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma","volume":"111","author":"Baba","year":"2020","journal-title":"Cancer Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41392-020-00323-3","article-title":"Advances in targeted therapy for esophageal cancer","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study","volume":"5","author":"Shah","year":"2019","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30169-8","article-title":"First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial","volume":"21","author":"Janjigian","year":"2020","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01926","article-title":"Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study","volume":"40","author":"Shen","year":"2022","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02469-3","article-title":"Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial","volume":"29","author":"Yin","year":"2023","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00060-8","article-title":"Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial","volume":"24","author":"Zhu","year":"2023","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02009","article-title":"Capecitabine or capecitabine plus oxaliplatin versus fluorouracil plus cisplatin in definitive concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (CRTCOESC): a multicenter, randomized, open-label, phase 3 trial","volume":"42","author":"Jia","year":"2024","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01601","article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02797-y","article-title":"First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study","volume":"30","author":"Li","year":"2024","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41467-025-67589-5","article-title":"Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial","volume":"17","author":"Wu","year":"2025","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-025-02477-4","article-title":"Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1\/2 trial (PALACE-2)","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"9676","DOI":"10.1038\/s41467-025-64660-z","article-title":"Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: phase 2 randomized trial (REVO)","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04022-w","article-title":"Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial","volume":"31","author":"Janjigian","year":"2025","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-025-02332-8","article-title":"Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring","volume":"24","author":"Jiao","year":"2025","journal-title":"Mol Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00287-6","article-title":"Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study","volume":"26","author":"Elimova","year":"2025","journal-title":"Lancet Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03783-8","article-title":"CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03781-w","article-title":"The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial","volume":"31","author":"Ruan","year":"2025","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/s1470-2045(25)00402-4","article-title":"First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b\/2 trial","volume":"27","author":"Sun","year":"2026","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00401-2","article-title":"Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"27","author":"Hsu","year":"2026","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-03044","article-title":"Tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, phase II trial (EC-CRT-002)","volume":"44","author":"Chen","year":"2026","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2517729","article-title":"Zanidatamab with and without Tislelizumab in HER2-positive gastroesophageal cancer","volume":"394","author":"Shitara","year":"2026","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.02.003","article-title":"Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649","volume":"37","author":"Janjigian","year":"2026","journal-title":"Ann Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.1038\/s41467-020-20019-0","article-title":"Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment","volume":"11","author":"Zheng","year":"2020","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1792881","article-title":"Pembrolizumab for the treatment of esophageal cancer","volume":"20","author":"Yamamoto","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3707","article-title":"Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: Systematic review and meta-analysis of 17 phase 3 randomized clinical trials","volume":"8","author":"Yoon","year":"2022","journal-title":"JAMA Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00918-1","article-title":"Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802)","volume":"6","author":"Bando","year":"2025","journal-title":"Nat Cancer"},{"key":"B63","article-title":"CTLA-4 and its inhibitors in esophageal cancer: efficacy of therapy and potential mechanisms of adverse events","volume":"13","author":"Tian","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/coc.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1680838","article-title":"Combination of PD-1\/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update","volume":"16","author":"Park","year":"2025","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-02958","article-title":"Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline update","volume":"44","author":"Shah","year":"2026","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0046-7","article-title":"Safety of combining radiotherapy with immune-checkpoint inhibition","volume":"15","author":"Hwang","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70345","article-title":"Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma","volume":"132","author":"Kachnic","year":"2026","journal-title":"Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61121-x","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100563","article-title":"Margetuximab with retifanlimab as first-line therapy in HER2+\/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A","volume":"7","author":"Catenacci","year":"2022","journal-title":"ESMO Open"},{"key":"B73","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41575-024-00912-5","article-title":"Sugemalimab with chemotherapy for advanced ESCC","volume":"21","author":"Ray","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01693-4","article-title":"Sugemalimab: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"B76","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920986518","article-title":"Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer","volume":"13","author":"Kotani","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.7058","article-title":"Trastuzumab deruxtecan versus ramucirumab-paclitaxel as second-line therapy for patients with HER2-positive gastric or GEJ adenocarcinoma","volume":"23","author":"Verhoeven","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B80","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41419-025-08278-5","article-title":"A TROP2-targeting ADC synergizes with oxidative phosphorylation inhibitor to enhance apoptosis in ESCC by suppressing the PI3K-AKT-mTOR signaling pathway","volume":"17","author":"Liu","year":"2025","journal-title":"Cell Death Dis"},{"key":"B81","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3892\/or.2025.8953","article-title":"Changing landscape of advanced esophageal squamous cell carcinoma: Breakthroughs in systemic therapies (Review)","volume":"54","author":"Li","year":"2025","journal-title":"Oncol Rep"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107521","article-title":"EVA1B facilitates esophageal squamous carcinoma progression and recruitment of immunosuppressive myeloid-derived suppressor cells in the tumor microenvironment","volume":"210","author":"Xia","year":"2024","journal-title":"Pharmacol Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115610","article-title":"Tumor associated macrophages in esophageal squamous carcinoma: Promising therapeutic implications","volume":"167","author":"Zhang","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1659048","article-title":"M2 macrophage infiltration drives tumor progression and identifies a multigene prognostic signature in esophageal cancer","volume":"16","author":"Wei","year":"2025","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1450603","article-title":"Current status of research on the mechanisms of tumor-associated macrophages in esophageal cancer progression","volume":"14","author":"Tang","year":"2024","journal-title":"Front Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01197-2","article-title":"Sex-specific prognostic effect of CD66b-positive tumor-infiltrating neutrophils (TANs) in gastric and esophageal adenocarcinoma","volume":"24","author":"Quaas","year":"2021","journal-title":"Gastric Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00262-024-03683-9","article-title":"Integrating bulk and single-cell sequencing data to construct a Scissor(+) dendritic cells prognostic model for predicting prognosis and immune responses in ESCC","volume":"73","author":"Cheng","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B88","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.1038\/s41467-021-27599-5","article-title":"Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment","volume":"12","author":"Dinh","year":"2021","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12967-024-05549-1","article-title":"Human esophageal cancer stem-like cells escape the cytotoxicity of natural killer cells via down-regulation of ULBP-1","volume":"22","author":"Tang","year":"2024","journal-title":"J Transl Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1775837","article-title":"The construction of CD8+ T cell-associated molecular subtypes in esophageal squamous cell carcinoma reveals tumor heterogeneity, tumor microenvironment, and immunotherapy","volume":"17","author":"Cao","year":"2026","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1788756","article-title":"Survival benefit and dynamics of CD8(+) T cells and tumor-associated macrophages in neoadjuvant immunochemotherapy vs. chemotherapy for locally advanced esophageal squamous cell carcinoma: an IPTW-adjusted real-world study","volume":"17","author":"Gan","year":"2026","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"9033","DOI":"10.1038\/s41467-024-53262-w","article-title":"Spatial dynamics of CD39(+)CD8(+) exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer","volume":"15","author":"Tanoue","year":"2024","journal-title":"Nat Commun"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.ccell.2023.09.011","article-title":"Progenitor-like exhausted SPRY1(+)CD8(+) T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"B94","doi-asserted-by":"publisher","first-page":"9097","DOI":"10.1038\/s41467-024-52977-0","article-title":"Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215959","article-title":"Th1-involved immune infiltrates improve neoadjuvant chemoradiotherapy response of esophageal squamous cell carcinoma","volume":"553","author":"Yuan","year":"2023","journal-title":"Cancer Lett"},{"key":"B96","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10495-025-02256-0","article-title":"Progenitor CD8(+) T cells and hyper-Treg crosstalk: a driver of immune checkpoint inhibitor resistance in esophageal squamous cell carcinoma","volume":"31","author":"Huang","year":"2026","journal-title":"Apoptosis"},{"key":"B97","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00262-025-03988-3","article-title":"The prognosis prediction value of CD69+ CD8+ tissue-resident memory T cell as a novel indicator of pathologic complete response heterogeneity following different neoadjuvant therapy regimen in esophageal squamous cell carcinoma","volume":"74","author":"Liu","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02562-3","article-title":"Characterization of CD103(+) CD8(+) tissue-resident T cells in esophageal squamous cell carcinoma: may be tumor reactive and resurrected by anti-PD-1 blockade","volume":"69","author":"Han","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B99","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1200\/JCO.2021.39.3_suppl.237","article-title":"Association of B cells in tumor microenvironment (TME) with clinical benefit to programmed cell death protein-1 (PD-1) blockade therapy in esophageal squamous cell carcinoma (ESCC)","volume":"39","author":"Guo","year":"2021","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14122","article-title":"Circulating exosomes from esophageal squamous cell carcinoma mediate the generation of B10 and PD-1(high) Breg cells","volume":"110","author":"Mao","year":"2019","journal-title":"Cancer Sci"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218309","article-title":"MFN2-CD36 interaction regulates mitochondrial lipid digestion in cancer-associated fibroblasts and promotes esophageal squamous cell carcinoma progression","volume":"643","author":"Shi","year":"2026","journal-title":"Cancer Lett"},{"key":"B102","doi-asserted-by":"publisher","first-page":"12024","DOI":"10.3390\/ijms262412024","article-title":"BGN secreted by cancer-associated fibroblasts promotes esophageal squamous cell carcinoma progression via activation of TLR4-mediated Erk and NF-\u03baB signaling pathways","volume":"26","author":"Yokoo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2024.2327692","article-title":"Lymphatic endothelial cell-mediated accumulation of CD177(+)Treg cells suppresses antitumor immunity in human esophageal squamous cell carcinoma","volume":"13","author":"Ma","year":"2024","journal-title":"Oncoimmunology"},{"key":"B104","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1053\/j.gastro.2025.02.032","article-title":"Evolution of esophageal adenocarcinoma from precursor lesion stem cells","volume":"169","author":"Xian","year":"2025","journal-title":"Gastroenterology"},{"key":"B105","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1038\/s41467-021-25539-x","article-title":"Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01294-3","article-title":"Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy","volume":"20","author":"Bhat","year":"2021","journal-title":"Mol Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-022-00398-3","article-title":"Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy","volume":"11","author":"Raskov","year":"2022","journal-title":"Oncogenesis"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.34","article-title":"The tumor microenvironment in esophageal cancer","volume":"35","author":"Lin","year":"2016","journal-title":"Oncogene"},{"key":"B111","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s12885-025-13801-0","article-title":"Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma","volume":"25","author":"Yin","year":"2025","journal-title":"BMC Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-3426-y","article-title":"Circulating CD14(+)HLA-DR(-\/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC","volume":"36","author":"Huang","year":"2015","journal-title":"Tumour Biol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2368","article-title":"IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus","volume":"5","author":"Chen","year":"2014","journal-title":"Oncotarget"},{"key":"B114","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.canlet.2021.06.009","article-title":"Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6\/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma","volume":"518","author":"Zhao","year":"2021","journal-title":"Cancer Lett"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1745988","article-title":"Regulating the regulators via targeting CD38 in the tumor microenvironment","volume":"17","author":"Dutta","year":"2026","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-14-3639","article-title":"CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer","volume":"75","author":"Karakasheva","year":"2015","journal-title":"Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1242\/jcs.115.1.99","article-title":"Dissection of HEF1-dependent functions in motility and transcriptional regulation","volume":"115","author":"Fashena","year":"2002","journal-title":"J Cell Sci"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0290","article-title":"NEDD9 promotes cancer stemness by recruiting myeloid-derived suppressor cells via CXCL8 in esophageal squamous cell carcinoma","volume":"18","author":"Yue","year":"2021","journal-title":"Cancer Biol Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0666-9","article-title":"Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal","volume":"21","author":"Baumann","year":"2020","journal-title":"Nat Immunol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy","volume":"21","author":"Wu","year":"2022","journal-title":"Mol Cancer"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136995","article-title":"Macrophage polarization states in the tumor microenvironment","volume":"22","author":"Boutilier","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02879-2","article-title":"The role of PD-1\/PD-L1 axis and macrophage in the progression and treatment of cancer","volume":"145","author":"Cai","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1096717","article-title":"Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13115","article-title":"Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting","volume":"54","author":"Xu","year":"2021","journal-title":"Cell Prolif"},{"key":"B125","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-020-01165-x","article-title":"CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis","volume":"19","author":"Yang","year":"2020","journal-title":"Mol Cancer"},{"key":"B126","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s11658-024-00592-8","article-title":"LINC00330\/CCL2 axis-mediated ESCC TAM reprogramming affects tumor progression","volume":"29","author":"Zhao","year":"2024","journal-title":"Cell Mol Biol Lett"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00903-z","article-title":"Tumor-associated macrophage (TAM)-derived CCL22 induces FAK addiction in esophageal squamous cell carcinoma (ESCC)","volume":"19","author":"Chen","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101055","article-title":"Tumor-associated macrophage (TAM)-secreted CCL22 confers cisplatin resistance of esophageal squamous cell carcinoma (ESCC) cells via regulating the activity of diacylglycerol kinase \u03b1 (DGK\u03b1)\/NOX4 axis","volume":"73","author":"Chen","year":"2024","journal-title":"Drug Resist Update"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgac043","article-title":"CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model","volume":"43","author":"Omstead","year":"2022","journal-title":"Carcinogenesis"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17710-1","article-title":"Cytotoxic anti-tumor drugs and tumor-associated macrophages synergistically surge PD-L1 expression in esophageal squamous cell carcinoma","volume":"32","author":"Hirose","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100130","article-title":"TAMs and PD-1 networking in esophageal cancer: literature review","volume":"7","author":"Yerolatsite","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.04.008","article-title":"Macrophage diversity in cancer revisited in the era of single-cell omics","volume":"43","author":"Ma","year":"2022","journal-title":"Trends Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9440(10)64554-3","article-title":"The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages","volume":"157","author":"Talks","year":"2000","journal-title":"Am J Pathol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1162032","article-title":"Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217874","article-title":"Characterizing chromosome instability reveals its association with lipid-associated macrophages and clonal evolution of lymph node metastasis in esophageal squamous cell carcinoma","volume":"628","author":"Dai","year":"2025","journal-title":"Cancer Lett"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.cell.2018.09.030","article-title":"High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy","volume":"175","author":"Gubin","year":"2018","journal-title":"Cell"},{"key":"B140","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"key":"B141","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cell.2020.06.032","article-title":"Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer","volume":"182","author":"Katzenelenbogen","year":"2020","journal-title":"Cell"},{"key":"B142","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cac2.70027","article-title":"Neutrophils in cancer: At the crucial crossroads of anti-tumor and pro-tumor","volume":"45","author":"Cai","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1373234","article-title":"IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma","volume":"7","author":"Chen","year":"2017","journal-title":"Oncoimmunology"},{"key":"B144","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40364-023-00493-6","article-title":"The role and metabolic adaptations of neutrophils in premetastatic niches","volume":"11","author":"Chen","year":"2023","journal-title":"biomark Res"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01210-8","article-title":"Targeting neutrophils for cancer therapy","volume":"24","author":"Kwak","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"B146","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41392-025-02242-7","article-title":"Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity","volume":"10","author":"Zhou","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2024.2305808","article-title":"The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer","volume":"20","author":"Ji","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0222-4","article-title":"Tumour-associated neutrophils in patients with cancer","volume":"16","author":"Shaul","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104999","article-title":"The central role of IL-17 in cancer stemness and immune evasion: A novel axis for overcoming immune checkpoint inhibitor resistance","volume":"217","author":"Wang","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1075260","article-title":"No NETs no TIME: Crosstalk between neutrophil extracellular traps and the tumor immune microenvironment","volume":"13","author":"Fang","year":"2022","journal-title":"Front Immunol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-024-01933-x","article-title":"Neutrophil extracellular traps in homeostasis and disease","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01749","article-title":"The emerging role of neutrophil extracellular traps (NETs) in tumor progression and metastasis","volume":"11","author":"Masucci","year":"2020","journal-title":"Front Immunol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-026-04304-3","article-title":"CXCL1-overexpressing cancer-associated fibroblasts stimulate hepatocellular carcinoma progression via neutrophil recruitment, NET formation, and immune suppression","volume":"75","author":"Bi","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008662","article-title":"CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs","volume":"12","author":"Xiong","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B155","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40364-026-00949-5","article-title":"Roles of neutrophil extracellular traps in cancer immunotherapy resistance and therapeutic targeting","volume":"14","author":"Li","year":"2026","journal-title":"biomark Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00571-6","article-title":"Neutrophils in cancer: heterogeneous and multifaceted","volume":"22","author":"Hedrick","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1440530","article-title":"Dendritic cell effector mechanisms and tumor immune microenvironment infiltration define TLR8 modulation and PD-1 blockade","volume":"15","author":"Ruiz-Torres","year":"2024","journal-title":"Front Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.0c00893","article-title":"Programmable delivery of immune adjuvant to tumor-infiltrating dendritic cells for cancer immunotherapy","volume":"20","author":"Liu","year":"2020","journal-title":"Nano Lett"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1153990","article-title":"Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Immunol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/s41419-025-08180-0","article-title":"The emerging role of dendritic cells in the tumor microenvironment: from antigen presentation to targeted immunotherapy","volume":"16","author":"Xie","year":"2025","journal-title":"Cell Death Dis"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci Transl Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2024.04.01","article-title":"Tumor-derived DEFB1 induces immune tolerance by inhibiting maturation of dendritic cell and impairing CD8+ T cell function in esophageal squamous cell carcinoma","volume":"36","author":"Duan","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"B164","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/hep.32099","article-title":"CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase","volume":"75","author":"Lin","year":"2022","journal-title":"Hepatology"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s42003-024-07341-9","article-title":"EZH2 elicits CD8(+) T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells","volume":"7","author":"Zhu","year":"2024","journal-title":"Commun Biol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1709852","article-title":"Terminally exhausted CD8(+) T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology","volume":"16","author":"Guo","year":"2025","journal-title":"Front Immunol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"CD8(+) T cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8(+) T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-024-09482-9","article-title":"FOXP4-AS1 promotes CD8(+) T cell exhaustion and esophageal cancer immune escape through USP10-stabilized PD-L1","volume":"72","author":"Shen","year":"2024","journal-title":"Immunol Res"},{"key":"B171","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13046-023-02697-y","article-title":"Spatial analysis of stromal signatures identifies invasive front carcinoma-associated fibroblasts as suppressors of anti-tumor immune response in esophageal cancer","volume":"42","author":"He","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B172","doi-asserted-by":"publisher","first-page":"26638","DOI":"10.1038\/s41598-025-10885-3","article-title":"The size of CD8+\u2009infiltrating T cells is a prognostic marker for esophageal squamous cell carcinoma","volume":"15","author":"Shigehara","year":"2025","journal-title":"Sci Rep"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-335642","article-title":"Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma","volume":"75","author":"Xiang","year":"2026","journal-title":"Gut"},{"key":"B174","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","article-title":"T cell exhaustion","volume":"42","author":"Baessler","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09539-1","article-title":"Proteotoxic stress response drives T cell exhaustion and immune evasion","volume":"647","author":"Wang","year":"2025","journal-title":"Nature"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2026.1827716","article-title":"T cell exhaustion landscapes and therapeutic modulation in cancer immunity","volume":"14","author":"Bautista","year":"2026","journal-title":"Front Cell Dev Biol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1038\/s41467-026-70751-2","article-title":"PD-1 antibody-bound progenitor-exhausted CD8(+) T cells in lymph nodes boost PD-1-blockade anti-tumor immunity in gastrointestinal cancer","volume":"17","author":"Nose","year":"2026","journal-title":"Nat Commun"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1172\/jci165673","article-title":"Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models","volume":"133","author":"Li","year":"2023","journal-title":"J Clin Invest"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.191220","article-title":"Faithful modeling of terminal CD8+T cell dysfunction and epigenetic stabilization in vitro","volume":"10","author":"Yousif","year":"2025","journal-title":"JCI Insight"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3496","article-title":"T-cell exhaustion: a potential target biomarker of the tumour microenvironment affecting oesophageal adenocarcinoma","volume":"25","author":"Peng","year":"2023","journal-title":"J Gene Med"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"key":"B185","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1387975","article-title":"Regulation of Treg cells by cytokine signaling and co-stimulatory molecules","volume":"15","author":"Zong","year":"2024","journal-title":"Front Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J Exp Med"},{"key":"B188","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s40425-019-0719-5","article-title":"Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8(+) T cells","volume":"7","author":"Mastelic-Gavillet","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B189","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/cas.14293","article-title":"Interleukin-33-nuclear factor-\u03baB-CCL2 signaling pathway promotes progression of esophageal squamous cell carcinoma by directing regulatory T cells","volume":"111","author":"Yue","year":"2020","journal-title":"Cancer Sci"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194821","article-title":"Differential expression of NEK kinase family members in esophageal adenocarcinoma and Barrett's esophagus","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2016.10.010","article-title":"B lymphocytes and cancer: a love-hate relationship","volume":"2","author":"Yuen","year":"2016","journal-title":"Trends Cancer"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1649812","article-title":"The dual immunomodulatory role of B cells in tumorigenesis: mechanisms, microenvironment crosstalk, and therapeutic implications","volume":"16","author":"Lv","year":"2025","journal-title":"Front Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-014745","article-title":"Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment","volume":"14","author":"Gao","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B194","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","article-title":"B cells, plasma cells and antibody repertoires in the tumour microenvironment","volume":"20","author":"Sharonov","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3390\/cimb48010106","article-title":"Regulatory B cells in tumor microenvironment","volume":"48","author":"Cai","year":"2026","journal-title":"Curr Issues Mol Biol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.981847","article-title":"Unraveling the role of Breg cells in digestive tract cancer and infectious immunity","volume":"13","author":"Moreira","year":"2022","journal-title":"Front Immunol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10456-021-09819-0","article-title":"Peritumoral B cells drive proangiogenic responses in HMGB1-enriched esophageal squamous cell carcinoma","volume":"25","author":"Kam","year":"2022","journal-title":"Angiogenesis"},{"key":"B198","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1795143","article-title":"A new era of natural killer cell immunotherapy in tumor treatment: latest advances and cutting-edge perspectives from basic research to clinical practice","volume":"17","author":"Du","year":"2026","journal-title":"Front Immunol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.621225","article-title":"Cytokines orchestrating the natural killer-myeloid cell crosstalk in the tumor microenvironment: implications for natural killer cell-based cancer immunotherapy","volume":"11","author":"Gaggero","year":"2020","journal-title":"Front Immunol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095951","article-title":"Regulation of ligands for the NKG2D activating receptor","volume":"31","author":"Raulet","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B202","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00262-025-04028-w","article-title":"Identification and validation of poor prognosis immunoevasive subtype of esophageal cancer with tumor-infiltrating SAMD3\u2009+\u2009NK cell abundance","volume":"74","author":"Huang","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.631713","article-title":"Harnessing the cDC1-NK cross-talk in the tumor microenvironment to battle cancer","volume":"11","author":"B\u00f6dder","year":"2020","journal-title":"Front Immunol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2026.1761070","article-title":"Cancer-associated fibroblast heterogeneity and its role in reshaping immunotherapy in solid cancers: potential strategies and clinical promise","volume":"14","author":"Zu","year":"2026","journal-title":"Front Cell Dev Biol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70415","article-title":"Cancer-associated fibroblasts: origin, classification, tumorigenicity, and targeting for cancer therapy","volume":"6","author":"Fan","year":"2025","journal-title":"MedComm (2020)"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102969","article-title":"Cancer-associated fibroblasts: accomplices in the tumor immune evasion","volume":"12","author":"Hilmi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc8346","article-title":"Laminin \u03b32-mediating T cell exclusion attenuates response to anti-PD-1 therapy","volume":"7","author":"Li","year":"2021","journal-title":"Sci Adv"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31730","article-title":"Dual TGF-\u03b2 and PD-1 blockade synergistically enhances MAGE-A3-specific CD8(+) T cell response in esophageal squamous cell carcinoma","volume":"143","author":"Chen","year":"2018","journal-title":"Int J Cancer"},{"key":"B209","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/cells14171398","article-title":"Cancer-associated fibroblasts in solid tumors and sarcomas: heterogeneity, function, and therapeutic implications","volume":"14","author":"Badran","year":"2025","journal-title":"Cells"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322924","article-title":"Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity","volume":"71","author":"Huang","year":"2022","journal-title":"Gut"},{"key":"B211","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40364-024-00656-z","article-title":"Functional heterogeneity of cancer-associated fibroblasts with distinct neoadjuvant immunotherapy plus chemotherapy response in esophageal squamous cell carcinoma","volume":"12","author":"Jiang","year":"2024","journal-title":"biomark Res"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-026-00905-z","article-title":"The role of ECM mechanics in cancer mechanotransduction through unraveling the molecular machinery of integrins, FAK, and YAP signaling","volume":"31","author":"Hassan","year":"2026","journal-title":"Cell Mol Biol Lett"},{"key":"B213","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7150\/ijbs.121356","article-title":"Mechanical microenvironment in tumor immune evasion: bidirectional regulation between matrix stiffness and immune cells and its therapeutic implications","volume":"22","author":"Ai","year":"2026","journal-title":"Int J Biol Sci"},{"key":"B214","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-022-01252-0","article-title":"Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy","volume":"15","author":"Jiang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10238-024-01490-1","article-title":"The crossroad between tumor and endothelial cells","volume":"24","author":"Ribatti","year":"2024","journal-title":"Clin Exp Med"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1199225","article-title":"Tumour associated endothelial cells: origin, characteristics and role in metastasis and anti-angiogenic resistance","volume":"14","author":"Yao","year":"2023","journal-title":"Front Physiol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.122510","article-title":"Tumor endothelial cells promote metastasis and cancer stem cell-like phenotype through elevated Epiregulin in esophageal cancer","volume":"6","author":"Sun","year":"2016","journal-title":"Am J Cancer Res"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15103","article-title":"Extracellular shuttling miR-21 contributes to esophageal cancers and human umbilical vein endothelial cell communication in the tumor microenvironment and promotes tumor angiogenesis by targeting phosphatase and tensinhomolog","volume":"14","author":"Zheng","year":"2023","journal-title":"Thorac Cancer"},{"key":"B219","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41392-025-02309-5","article-title":"Aberrant Notch-signaling promotes tumor angiogenesis in esophageal squamous-cell carcinoma","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100607","article-title":"Single-cell transcriptomics of endothelial cells in upper and lower human esophageal squamous cell carcinoma","volume":"29","author":"Sha","year":"2022","journal-title":"Curr Oncol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1367875","article-title":"Endothelial cells in tumor microenvironment: insights and perspectives","volume":"15","author":"Leone","year":"2024","journal-title":"Front Immunol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23909","article-title":"GPR87 promotes angiogenesis in esophageal squamous cell carcinoma via VEGFA regulation","volume":"64","author":"Zhu","year":"2025","journal-title":"Mol Carcinog"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2023.104506","article-title":"IL-33-expressing microvascular endothelial cells in human esophageal squamous cell carcinoma: implications for pathological features and prognosis","volume":"147","author":"Liu","year":"2023","journal-title":"Microvasc Res"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S103179","article-title":"Esophageal cancer stem cells and implications for future therapeutics","volume":"9","author":"Qian","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B225","doi-asserted-by":"publisher","first-page":"16105","DOI":"10.1038\/cddiscovery.2016.105","article-title":"Cancer stem-like cells can be induced through dedifferentiation under hypoxic conditions in glioma, hepatoma and lung cancer","volume":"3","author":"Wang","year":"2017","journal-title":"Cell Death Discov"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2015.02.015","article-title":"The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells","volume":"16","author":"Plaks","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-24-1185","article-title":"Hypoxia-induced senescent fibroblasts secrete IGF1 to promote cancer stemness in esophageal squamous cell carcinoma","volume":"85","author":"Ou","year":"2025","journal-title":"Cancer Res"},{"key":"B228","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ccell.2025.02.009","article-title":"Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis","volume":"43","author":"Chang","year":"2025","journal-title":"Cancer Cell"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.387","article-title":"IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma","volume":"37","author":"Qiao","year":"2018","journal-title":"Oncogene"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-24-0030","article-title":"Natural killer cell regulation of breast cancer stem cells mediates metastatic dormancy","volume":"84","author":"Bushnell","year":"2024","journal-title":"Cancer Res"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-026-00928-w","article-title":"The sleeping threat: targeting cancer dormancy to transform metastasis therapy","volume":"26","author":"Aguirre-Ghiso","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2407506121","article-title":"QSOX1 facilitates dormant esophageal cancer stem cells to evade immune elimination via PD-L1 upregulation and CD8 T cell exclusion","volume":"121","author":"Wei","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14247-z","article-title":"Cancer stem cells of esophageal adenocarcinoma are suppressed by inhibitors of TRPV2 and SLC12A2","volume":"30","author":"Shiozaki","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202403019R","article-title":"Metabolic reprogramming of glycolysis, lipids, and amino acids in tumors: impact on CD8+ T cell function and targeted therapeutic strategies","volume":"39","author":"Liang","year":"2025","journal-title":"FASEB J"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1559546","article-title":"Targeting glycolysis in esophageal squamous cell carcinoma: single-cell and multi-omics insights for risk stratification and personalized therapy","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1416472","article-title":"Glycolysis in the tumor microenvironment: a driver of cancer progression and a promising therapeutic target","volume":"12","author":"Zhao","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B238","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13148-024-01682-2","article-title":"Lactylation: the novel histone modification influence on gene expression, protein function, and disease","volume":"16","author":"Hu","year":"2024","journal-title":"Clin Epigenet"},{"key":"B239","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s40164-025-00719-3","article-title":"Lactate and lactylation in cancer: drivers of immune suppression and microenvironmental reprogramming","volume":"14","author":"Ji","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1506849","article-title":"Crosstalk between lactate and tumor-associated immune cells: clinical relevance and insight","volume":"14","author":"Sun","year":"2024","journal-title":"Front Oncol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0226-8","article-title":"Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages","volume":"19","author":"Bohn","year":"2018","journal-title":"Nat Immunol"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14998","article-title":"Lactate secreted by esophageal cancer cells induces M2 macrophage polarization via the AKT\/ERK pathway","volume":"14","author":"Zhang","year":"2023","journal-title":"Thorac Cancer"},{"key":"B243","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1186\/s12885-022-09956-9","article-title":"The acidic tumor microenvironment enhances PD-L1 expression via activation of STAT3 in MDA-MB-231 breast cancer cells","volume":"22","author":"Kwon","year":"2022","journal-title":"BMC Cancer"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1038\/s44319-024-00365-6","article-title":"Acidic pH can attenuate immune killing through inactivation of perforin","volume":"26","author":"Hodel","year":"2025","journal-title":"EMBO Rep"},{"key":"B245","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13046-023-02821-y","article-title":"Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase\/STAT3\/VEGFA pathway","volume":"42","author":"Yuan","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218548","article-title":"Lactylation of HIF-1\u03b1 at K172 drives HIF-1 complex assembly to promote hypoxia-induced immune evasion in esophageal squamous cell carcinoma","volume":"651","author":"Cong","year":"2026","journal-title":"Cancer Lett"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.065953","article-title":"Hypoxic link between cancer cells and the immune system: the role of adenosine and lactate","volume":"33","author":"Alvarado-Ortiz","year":"2025","journal-title":"Oncol Res"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i3.103450","article-title":"Hypoxia-inducible factor 1-alpha and lactate dehydrogenase-A axis in metabolic changes and aggression in esophageal squamous-cell carcinoma","volume":"17","author":"Chen","year":"2025","journal-title":"World J Gastrointest Oncol"},{"key":"B249","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","article-title":"Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09278-3","article-title":"Neutrophils drive vascular occlusion, tumour necrosis and metastasis","volume":"645","author":"Adrover","year":"2025","journal-title":"Nature"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174189","article-title":"Hypoxic regulation of neutrophils in cancer","volume":"20","author":"Triner","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02358","article-title":"Hypoxia modifies the transcriptome of human NK cells, modulates their immunoregulatory profile, and influences NK cell subset migration","volume":"9","author":"Parodi","year":"2018","journal-title":"Front Immunol"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn1849","article-title":"Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments","volume":"10","author":"Kennedy","year":"2024","journal-title":"Sci Adv"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26608","article-title":"Oxygen in the tumor microenvironment: effects on dendritic cell function","volume":"10","author":"Paardekooper","year":"2019","journal-title":"Oncotarget"},{"key":"B255","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/j.immuni.2025.09.003","article-title":"Intra-tumoral hypoxia promotes CD8(+) T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4","volume":"58","author":"Alicea Pauneto","year":"2025","journal-title":"Immunity"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1878140","article-title":"Tryptophan metabolism in tumor immune escape: mechanisms, cellular crosstalk, and therapeutic opportunities","volume":"17","author":"Chen","year":"2026","journal-title":"Front Immunol"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217680","article-title":"The arginine metabolism and its deprivation in cancer therapy","volume":"620","author":"Feng","year":"2025","journal-title":"Cancer Lett"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.7150\/thno.105276","article-title":"Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/384726","article-title":"Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma","volume":"2011","author":"Zhang","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.7150\/thno.82920","article-title":"The role of lipid metabolic reprogramming in tumor microenvironment","volume":"13","author":"Yang","year":"2023","journal-title":"Theranostics"},{"key":"B262","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10020-025-01132-6","article-title":"PKN2 enhances the immunosuppressive activity of polymorphonuclear myeloid-derived suppressor cells in esophageal carcinoma by mediating fatty acid oxidation","volume":"31","author":"Fu","year":"2025","journal-title":"Mol Med"},{"key":"B263","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","article-title":"CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability","volume":"33","author":"Ma","year":"2021","journal-title":"Cell Metab"},{"key":"B264","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","article-title":"Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8(+) T cells in tumors","volume":"54","author":"Xu","year":"2021","journal-title":"Immunity"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111281","article-title":"Metabolic crosstalk: Extracellular ATP and the tumor microenvironment in cancer progression and therapy","volume":"121","author":"Shukla","year":"2024","journal-title":"Cell Signal"},{"key":"B266","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol Cancer"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2023.63","article-title":"Unlocking antitumor immunity with adenosine receptor blockers","volume":"6","author":"Remley","year":"2023","journal-title":"Cancer Drug Resist"},{"key":"B268","doi-asserted-by":"publisher","first-page":"31653","DOI":"10.1038\/s41598-024-80226-3","article-title":"D-loop mutations in mitochondrial DNA are a risk factor for chemotherapy resistance in esophageal cancer","volume":"14","author":"Harino","year":"2024","journal-title":"Sci Rep"},{"key":"B269","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s12967-022-03594-2","article-title":"Low mitochondrial DNA copy number induces chemotherapy resistance via epithelial-mesenchymal transition by DNA methylation in esophageal squamous cancer cells","volume":"20","author":"Kubo","year":"2022","journal-title":"J Transl Med"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1423629","article-title":"Metabolic reprogramming in esophageal squamous cell carcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32301","article-title":"High metabolic rate and stem cell characteristics of esophageal cancer stem-like cells depend on the Hsp27-AKT-HK2 pathway","volume":"145","author":"Liu","year":"2019","journal-title":"Int J Cancer"},{"key":"B272","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1101\/gad.333146.119","article-title":"CDK7 regulates organ size and tumor growth by safeguarding the Hippo pathway effector Yki\/Yap\/Taz in the nucleus","volume":"34","author":"Cho","year":"2020","journal-title":"Genes Dev"},{"key":"B273","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-023-01555-9","article-title":"CDK7-YAP-LDHD axis promotes D-lactate elimination and ferroptosis defense to support cancer stem cell-like properties","volume":"8","author":"Lv","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010048","article-title":"Esophageal cancer stem-like cells resist ferroptosis-induced cell death by active Hsp27-GPX4 pathway","volume":"12","author":"Liu","year":"2021","journal-title":"Biomolecules"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189471","article-title":"Mitochondrial dynamics and metabolic attributes regulate function of natural killer cell and infiltration in tumor microenvironment modulating disease progression","volume":"1880","author":"Ghosh","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B276","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrm3904","article-title":"Remodelling the extracellular matrix in development and disease","volume":"15","author":"Bonnans","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1659077","article-title":"Progenitor-exhausted T cell as prognostic indicator in esophageal squamous cell carcinoma: illuminating their key contribution to tumor immunity","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1679365","article-title":"Advancing immunotherapy for esophageal cancer: decoding the roles of PD-L1, TME, and tumor-intrinsic biomarkers","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02235-9","article-title":"Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors","volume":"128","author":"Hayashi","year":"2023","journal-title":"Br J Cancer"},{"key":"B280","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12967-026-07950-4","article-title":"Spatial distribution analysis of tertiary lymphoid structures in esophageal squamous cell carcinoma predicts patient survival and response to neoadjuvant chemo-immunotherapy","volume":"24","author":"Wang","year":"2026","journal-title":"J Transl Med"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-026-02735-1","article-title":"Radiotherapy and tertiary lymphoid structures: balancing immune activation and immune damage in cancer immunotherapy","author":"Zhang","year":"2026","journal-title":"Mol Cancer"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217178","article-title":"Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies","volume":"601","author":"Huang","year":"2024","journal-title":"Cancer Lett"},{"key":"B283","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-024-01947-5","article-title":"Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwae150","article-title":"Immune-tumor interaction dictates spatially directed evolution of esophageal squamous cell carcinoma","volume":"11","author":"Zhou","year":"2024","journal-title":"Natl Sci Rev"},{"key":"B285","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00262-024-03848-6","article-title":"Integrative analyses of bulk and single-cell RNA-seq reveals the correlation between SPP1(+) macrophages and resistance to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma","volume":"73","author":"Geng","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B286","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41392-025-02306-8","article-title":"Comprehensive genomic and transcriptomic analyses reveal prognostic stratification for esophageal squamous cell carcinoma","volume":"10","author":"Gao","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2024.01.008","article-title":"Cancer-associated fibroblasts in esophageal cancer","volume":"17","author":"Dunbar","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-24-1853","article-title":"Preclinical evaluation of AZD6422, an armored chimeric antigen receptor T cell targeting CLDN18.2 in gastric, pancreatic, and esophageal cancers","volume":"30","author":"Barrett","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"B290","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1186\/s12967-026-08004-5","article-title":"Dissecting the immunosuppressive microenvironment of LAMA3\u2009+\u2009malignant cells and SPP1\u2009+\u2009macrophages in esophageal squamous cell carcinoma using single-cell and spatial transcriptomics","volume":"24","author":"Hong","year":"2026","journal-title":"J Transl Med"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12156","article-title":"The role of myeloid-derived suppressor cells in gastrointestinal cancer","volume":"41","author":"Cui","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013959","article-title":"An immune-privileged niche mediates immunotherapy resistance in esophageal carcinoma","volume":"14","author":"Wan","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B293","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41392-023-01388-6","article-title":"Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202505806","article-title":"tRNA-derived fragment tRF-22 promotes immunosuppression by inhibiting HnRNPAB ubiquitination in esophageal squamous cell carcinoma","volume":"13","author":"Pan","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02683-x","article-title":"SPP1 represents a therapeutic target that promotes the progression of oesophageal squamous cell carcinoma by driving M2 macrophage infiltration","volume":"130","author":"Wang","year":"2024","journal-title":"Br J Cancer"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113422","article-title":"FOXF2 suppressed esophageal squamous cell carcinoma by reducing M2 TAMs via modulating RNF144A-FTO axis","volume":"143","author":"Han","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B297","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13073-025-01465-1","article-title":"Multi-omics analysis reveals immunosuppression in oesophageal squamous cell carcinoma induced by creatine accumulation and HK3 deficiency","volume":"17","author":"Gao","year":"2025","journal-title":"Genome Med"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110213","article-title":"P-hydroxylcinnamaldehyde induces tumor-associated macrophage polarization toward the M1 type by regulating the proteome and inhibits ESCC in vivo and in vitro","volume":"119","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgad087","article-title":"Sitravatinib combined with PD-1 blockade enhances cytotoxic T-cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma","volume":"45","author":"Sweeney","year":"2024","journal-title":"Carcinogenesis"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.123646","article-title":"Extracellular vesicles derived from irradiated tumor cells foster immunosuppressive macrophages formation to promote esophageal squamous cell carcinoma immune evasion","volume":"22","author":"Jiang","year":"2026","journal-title":"Int J Biol Sci"},{"key":"B301","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.10.028","article-title":"Radiation-induced remodeling of the tumor microenvironment through tumor cell-intrinsic expression of cGAS-STING in esophageal squamous cell carcinoma","volume":"115","author":"Nakajima","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B302","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-20-0917","article-title":"Neoadjuvant chemotherapy induces IL34 signaling and promotes chemoresistance via tumor-associated macrophage polarization in esophageal squamous cell carcinoma","volume":"19","author":"Nakajima","year":"2021","journal-title":"Mol Cancer Res"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887189","article-title":"Advances in human dendritic cell-based immunotherapy against gastrointestinal cancer","volume":"13","author":"Ni","year":"2022","journal-title":"Front Immunol"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352454","article-title":"Innovative prognostic modeling in ESCC: leveraging scRNA-seq and bulk-RNA for dendritic cell heterogeneity analysis","volume":"15","author":"Shi","year":"2024","journal-title":"Front Immunol"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000691","article-title":"Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate na\u00efve and memory NY-ESO-1-specific CD8(+) T cells","volume":"8","author":"Masterman","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B307","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00262-022-03227-z","article-title":"TIGIT blockade enhances tumor response to radiotherapy via a CD103\u2009+\u2009dendritic cell-dependent mechanism","volume":"72","author":"Zhao","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104971","article-title":"Genomic profiling and associated B cell lineages delineate the efficacy of neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma","volume":"100","author":"Zhang","year":"2024","journal-title":"EBioMedicine"},{"key":"B309","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1233085","article-title":"Exploring the dual role of B cells in solid tumors: implications for head and neck squamous cell carcinoma","volume":"14","author":"Bao","year":"2023","journal-title":"Front Immunol"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.5ma0720-710rrr","article-title":"High infiltration of B cells in tertiary lymphoid structures, TCR oligoclonality, and neoantigens are part of esophageal squamous cell carcinoma microenvironment","volume":"108","author":"Barros","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.896627","article-title":"Characterization of the intra-tumoral B cell immunoglobulin repertoire is of prognostic value for esophageal squamous cell carcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B312","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.879398","article-title":"B cells in tumor microenvironment associated with the clinical benefit to programmed cell death protein-1 blockade therapy in patients with advanced esophageal squamous cell carcinoma","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"B313","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-025-00944-2","article-title":"Characterization of tertiary lymphoid structure identifies competitive binding of CD40 and STING with TRAF2 driving IRF4-mediated B cell activation in esophageal squamous cell carcinoma","volume":"32","author":"Zheng","year":"2025","journal-title":"Cancer Gene Ther"},{"key":"B314","doi-asserted-by":"publisher","DOI":"10.7150\/thno.118269","article-title":"MIF-expressing tumor cells mediate immunotherapeutic resistance in esophageal squamous cell carcinoma","volume":"16","author":"Song","year":"2026","journal-title":"Theranostics"},{"key":"B315","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102532","article-title":"Targeting senescent EGR1(+) B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma","volume":"7","author":"Zhou","year":"2026","journal-title":"Cell Rep Med"},{"key":"B316","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.trsl.2024.11.002","article-title":"Lympho-myeloid aggregate-infiltrating CD20(+) B cells display a double-negative phenotype and correlate with poor prognosis in esophageal squamous cell carcinoma","volume":"275","author":"Huang","year":"2025","journal-title":"Transl Res"},{"key":"B317","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0628","article-title":"The mechanisms and clinical significance of CD8(+) T cell exhaustion in anti-tumor immunity","volume":"22","author":"Zhong","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B318","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12967-025-06178-y","article-title":"Integrative analysis of T cell-mediated tumor killing-related genes reveals KIF11 as a novel therapeutic target in esophageal squamous cell carcinoma","volume":"23","author":"Cheng","year":"2025","journal-title":"J Transl Med"},{"key":"B319","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1257266","article-title":"Role of cancer-associated fibroblasts in the progression, therapeutic resistance and targeted therapy of oesophageal squamous cell carcinoma","volume":"13","author":"Xue","year":"2023","journal-title":"Front Oncol"},{"key":"B320","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s10142-024-01447-3","article-title":"The mechanism of MMP14-positive tumor-associated fibroblast subsets in inhibiting PD-1 immunotherapy for esophageal cancer through exosomal tsRNA-10522","volume":"24","author":"Wang","year":"2024","journal-title":"Funct Integr Genomics"},{"key":"B321","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13062-025-00694-z","article-title":"RGS16-driven cancer-associated fibroblasts promote esophageal squamous cell carcinoma progression via the MDK-SDC1 axis-mediated intercellular crosstalk","volume":"20","author":"Wu","year":"2025","journal-title":"Biol Direct"},{"key":"B322","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1586790","article-title":"WISP1 drives esophageal squamous cell carcinoma progression via modulation of cancer-associated fibroblasts and immune microenvironment","volume":"16","author":"Yi","year":"2025","journal-title":"Front Immunol"},{"key":"B323","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12943-022-01666-x","article-title":"The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy","volume":"21","author":"Croft","year":"2022","journal-title":"Mol Cancer"},{"key":"B324","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013144","article-title":"Endothelial cells as targets of immune checkpoint blockade","volume":"13","author":"Korman","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B325","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s12276-024-01369-x","article-title":"Single-cell RNA sequencing and spatial transcriptomics of esophageal squamous cell carcinoma with lymph node metastases","volume":"57","author":"Guo","year":"2025","journal-title":"Exp Mol Med"},{"key":"B326","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153455","article-title":"Quercetin inhibits invasion and angiogenesis of esophageal cancer cells","volume":"222","author":"Liu","year":"2021","journal-title":"Pathol Res Pract"},{"key":"B327","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00883-y","article-title":"Tumor-associated endothelial cells in tumor immune escape and immunotherapy: multifaceted roles and treatment approaches","volume":"14","author":"Zheng","year":"2025","journal-title":"biomark Res"},{"key":"B328","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061481","article-title":"Linking cancer stem cell plasticity to therapeutic resistance-mechanism and novel therapeutic strategies in esophageal cancer","volume":"9","author":"Zhou","year":"2020","journal-title":"Cells"},{"key":"B329","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13568","article-title":"Integrin \u03b17 is a functional cancer stem cell surface marker in oesophageal squamous cell carcinoma","volume":"7","author":"Ming","year":"2016","journal-title":"Nat Commun"},{"key":"B330","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154043","article-title":"Cancer stem cells in esophageal squamous cell carcinoma","volume":"237","author":"Sun","year":"2022","journal-title":"Pathol Res Pract"},{"key":"B331","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105144","article-title":"Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer","volume":"161","author":"Yi","year":"2020","journal-title":"Pharmacol Res"},{"key":"B332","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105301","article-title":"Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective","volume":"107","author":"Liu","year":"2024","journal-title":"EBioMedicine"},{"key":"B333","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000002426","article-title":"Metabolic reprogramming in the immunosuppression of tumor-associated macrophages","volume":"135","author":"Wang","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"B334","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2520427123","article-title":"Multiomics identifies a cholesterol-TFEB-PLD3-TLR9 axis driving immunosuppressive tumor-associated macrophage polarization in esophageal squamous cell carcinoma","volume":"123","author":"Tan","year":"2026","journal-title":"Proc Natl Acad Sci USA"},{"key":"B335","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41419-025-07787-7","article-title":"ISCU-p53 axis orchestrates macrophage polarization to dictate immunotherapy response in esophageal squamous cell carcinoma","volume":"16","author":"Luo","year":"2025","journal-title":"Cell Death Dis"},{"key":"B336","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70434","article-title":"Machine learning-based glycolipid metabolism gene signature predicts prognosis and immune landscape in oesophageal squamous cell carcinoma","volume":"29","author":"Zhu","year":"2025","journal-title":"J Cell Mol Med"},{"key":"B337","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxaf003","article-title":"Beneficial effects on T cells by photodynamic therapy with talaporfin enhance cancer immunotherapy","volume":"37","author":"Ezzaldeen","year":"2025","journal-title":"Int Immunol"},{"key":"B338","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2554","article-title":"Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","volume":"17","author":"Mitsunaga","year":"2011","journal-title":"Nat Med"},{"key":"B339","doi-asserted-by":"publisher","first-page":"20152","DOI":"10.1038\/s41598-022-24313-3","article-title":"Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in the tumor microenvironment","volume":"12","author":"Sato","year":"2022","journal-title":"Sci Rep"},{"key":"B340","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41598-021-81465-4","article-title":"Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer","volume":"11","author":"Katsube","year":"2021","journal-title":"Sci Rep"},{"key":"B341","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02864-5","article-title":"Efficacy and safety of talaporfin sodium photodynamic therapy as a salvage treatment for locally recurrent esophageal squamous cell carcinoma","volume":"30","author":"Tanaka","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B342","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-020-00799-6","article-title":"Evaluation of the efficacy and safety of salvage photodynamic therapy by talaporfin sodium for cervical esophageal cancers and lesions larger than 3 cm","volume":"18","author":"Hayashi","year":"2021","journal-title":"Esophagus"},{"key":"B343","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c07488","article-title":"Identifying TOPK and hypoxia hallmarks in esophageal tumors for photodynamic\/chemo\/immunotherapy and liver metastasis inhibition with nanocarriers","volume":"17","author":"Shi","year":"2023","journal-title":"ACS Nano"},{"key":"B344","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1024576","article-title":"Advancements in photodynamic therapy of esophageal cancer","volume":"12","author":"Bartusik-Aebisher","year":"2022","journal-title":"Front Oncol"},{"key":"B345","doi-asserted-by":"publisher","DOI":"10.1039\/d4nr05114a","article-title":"Nanoparticle-based drug delivery systems: opportunities and challenges in the treatment of esophageal squamous cell carcinoma (ESCC)","volume":"17","author":"Peng","year":"2025","journal-title":"Nanoscale"},{"key":"B346","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661357","article-title":"Indoleamine 2,3-dioxygenase 1 inhibitor-loaded nanosheets enhance CAR-T cell function in esophageal squamous cell carcinoma","volume":"12","author":"Shao","year":"2021","journal-title":"Front Immunol"},{"key":"B347","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202411930","article-title":"Paclitaxel\/luteolin coloaded dual-functional liposomes for esophageal cancer therapy","volume":"12","author":"Sun","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B348","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c12387","article-title":"Nanomaterials-involved tumor-associated macrophages' reprogramming for antitumor therapy","volume":"18","author":"Li","year":"2024","journal-title":"ACS Nano"},{"key":"B349","doi-asserted-by":"publisher","DOI":"10.1039\/d4nr01140f","article-title":"Macrophage reprogramming combined with enhanced photodynamic therapy increases the patency of Malignant esophageal obstruction after stenting","volume":"16","author":"Xu","year":"2024","journal-title":"Nanoscale"},{"key":"B350","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1233476","article-title":"Nanodrugs systems for therapy and diagnosis of esophageal cancer","volume":"11","author":"Zhang","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"B351","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","article-title":"Recent developments in immunotherapy for gastrointestinal tract cancers","volume":"17","author":"Chong","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B352","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1665488","article-title":"Recent advances in adoptive cell therapy for cancer immunotherapy","volume":"16","author":"Qian","year":"2025","journal-title":"Front Immunol"},{"key":"B353","doi-asserted-by":"publisher","first-page":"28958","DOI":"10.1038\/s41598-025-12337-4","article-title":"The expression of the tight junction protein and therapeutical target Claudin 18.2 is heterogeneously distributed within esophageal and gastric adenocarcinoma","volume":"15","author":"Pak","year":"2025","journal-title":"Sci Rep"},{"key":"B354","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"B355","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1589379","article-title":"Harnessing NKG2D CAR-T cells with radiotherapy: a novel approach for esophageal squamous cell carcinoma treatment","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B356","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03813-5","article-title":"Noncanonical and mortality-defining toxicities of CAR T cell therapy","volume":"31","author":"Rejeski","year":"2025","journal-title":"Nat Med"},{"key":"B357","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B358","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s12672-025-03747-x","article-title":"Study on the in vitro and in vivo killing effects of PD-1 antibody-secreting c-Met-targeted CAR-T cells on esophageal cancer cell line ECA109","volume":"16","author":"Peng","year":"2025","journal-title":"Discov Oncol"},{"key":"B359","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13071598","article-title":"Interleukin 21-Armed EGFR-VHH-CAR-T cell therapy for the treatment of esophageal squamous cell carcinoma","volume":"13","author":"Zhang","year":"2025","journal-title":"Biomedicines"},{"key":"B360","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-024-03249-w","article-title":"NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route","volume":"24","author":"Amissah","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B361","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12032-024-02475-6","article-title":"Cancer\/testis antigen expression and co-expression patterns in gastroesophageal adenocarcinoma","volume":"41","author":"Kalvapudi","year":"2024","journal-title":"Med Oncol"},{"key":"B362","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S99195","article-title":"Upregulation of MAGEA4 correlates with poor prognosis in patients with early stage of esophageal squamous cell carcinoma","volume":"9","author":"Tang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B363","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70020","article-title":"NY-ESO-1 antigen: A promising frontier in cancer immunotherapy","volume":"14","author":"Alsalloum","year":"2024","journal-title":"Clin Transl Med"},{"key":"B364","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-14-1559","article-title":"Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer","volume":"21","author":"Kageyama","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B365","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24232","article-title":"Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells","volume":"9","author":"Kato","year":"2018","journal-title":"Oncotarget"},{"key":"B366","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006334","article-title":"Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen","volume":"11","author":"Chen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B367","doi-asserted-by":"publisher","DOI":"10.62347\/nvfb3780","article-title":"Personalized mRNA vaccine combined with PD-1 inhibitor therapy in a patient with advanced esophageal squamous cell carcinoma","volume":"14","author":"Wang","year":"2024","journal-title":"Am J Cancer Res"},{"key":"B368","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101118","article-title":"Identification of HLA-A2-restricted mutant epitopes from neoantigens of esophageal squamous cell carcinoma","volume":"9","author":"Wang","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B369","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.792779","article-title":"Integrative genomic analyses of 1,145 patient samples reveal new biomarkers in esophageal squamous cell carcinoma","volume":"8","author":"Zou","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B370","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3659","article-title":"Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance","volume":"48","author":"Secrier","year":"2016","journal-title":"Nat Genet"},{"key":"B371","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1658670","article-title":"Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B372","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-014562","article-title":"Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma","volume":"14","author":"Zhang","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B373","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2025.0267","article-title":"Current progress in neoantigen-based dendritic cell vaccines for solid tumors","volume":"22","author":"Li","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B374","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B375","doi-asserted-by":"publisher","first-page":"7269","DOI":"10.1038\/s41467-025-62647-4","article-title":"Sensitive neoantigen discovery by real-time mutanome-guided immunopeptidomics","volume":"16","author":"Shapiro","year":"2025","journal-title":"Nat Commun"},{"key":"B376","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","article-title":"Oncolytic viruses: advanced strategies in cancer therapy","volume":"11","author":"Xiao","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B377","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41420-023-01466-2","article-title":"Recombinant measles virus vaccine rMV-Hu191 exerts an oncolytic effect on esophageal squamous cell carcinoma via caspase-3\/GSDME-mediated pyroptosis","volume":"9","author":"Wu","year":"2023","journal-title":"Cell Death Discov"},{"key":"B378","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2021.04.043","article-title":"Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments","volume":"153","author":"Shirakawa","year":"2021","journal-title":"Eur J Cancer"},{"key":"B379","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002224","article-title":"Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I\/II clinical trial","volume":"9","author":"Zhang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B380","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.05.032","article-title":"Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: a review","volume":"359","author":"Beishenaliev","year":"2023","journal-title":"J Control Release"},{"key":"B381","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2024.1352014","article-title":"Design and engineering of bispecific antibodies: insights and practical considerations","volume":"12","author":"Madsen","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"key":"B382","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-3770","article-title":"Bispecific immunomodulatory antibodies for cancer immunotherapy","volume":"27","author":"Blanco","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B383","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1450710","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE\u00ae) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"Oncoimmunology"},{"key":"B384","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02187-9","article-title":"Catumaxomab: first approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"key":"B385","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006704","article-title":"CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation","volume":"11","author":"Gao","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B386","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s00262-024-03769-4","article-title":"First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial","volume":"73","author":"Zhao","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B387","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"B388","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012869","article-title":"Cadonilimab combined with taxane and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma: an open-label, multicenter phase II trial","volume":"13","author":"Qu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B389","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3390\/cancers17050851","article-title":"Current advances in immunotherapy management of esophageal cancer","volume":"17","author":"Pyreddy","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B390","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov"},{"key":"B391","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.11.011","article-title":"Turning cold into hot: emerging strategies to fire up the tumor microenvironment","volume":"11","author":"Ma","year":"2025","journal-title":"Trends Cancer"},{"key":"B392","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02341-9","article-title":"Single-cell multi-omic and spatial profiling of esophageal squamous cell carcinoma reveals the immunosuppressive role of GPR116(+) pericytes in cancer metastasis","volume":"57","author":"Pei","year":"2025","journal-title":"Nat Genet"},{"key":"B393","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2022.12.004","article-title":"Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"B394","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1634413","article-title":"Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming","volume":"16","author":"Chen","year":"2025","journal-title":"Front Pharmacol"},{"key":"B395","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41392-025-02446-x","article-title":"Single-cell atlas of the esophageal squamous cell carcinoma immune ecosystem to predict immunotherapy response","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B396","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007847","article-title":"High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy","volume":"11","author":"Han","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B397","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202417593","article-title":"Immunotyping the tumor microenvironment reveals molecular heterogeneity for personalized immunotherapy in cancer","volume":"12","author":"Zeng","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B398","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1717062","article-title":"Reprogramming the tumor microenvironment to overcome immunotherapy resistance in pancreatic cancer","volume":"16","author":"Hui","year":"2025","journal-title":"Front Immunol"},{"key":"B399","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2025.0346","article-title":"Current status of management of immune-related adverse events and practical needs for oncologist education","volume":"22","author":"Tian","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B400","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1810121","article-title":"Key immune checkpoint inhibitor-associated toxicities: from molecular mechanisms to clinical management","volume":"17","author":"Lu","year":"2026","journal-title":"Front Pharmacol"},{"key":"B401","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1030147","article-title":"The effect of organ-specific tumor microenvironments on response patterns to immunotherapy","volume":"13","author":"Conway","year":"2022","journal-title":"Front Immunol"},{"key":"B402","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20242282","article-title":"Tumor cell heterogeneity drives spatial organization of the intratumoral immune response","volume":"222","author":"Tanaka","year":"2025","journal-title":"J Exp Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1926551\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:38:04Z","timestamp":1789385884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1926551\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":402,"alternative-id":["10.3389\/fimmu.2026.1926551"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1926551","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1926551"}}